Robyn Goforth, PhD serves as Vice President of Technology Assessment at VIC Tech. In this role, Dr. Goforth leads VIC’s Opportunity Assessment Team, which is responsible for the technical and commercial evaluation of life science technologies available for licensing from research institutions worldwide. Her team provides investment recommendations to VIC’s Board of Directors, identifying innovative technologies with robust intellectual property foundations for the formation of new companies within VIC’s portfolio.
Dr. Goforth also plays pivotal roles at two VIC portfolio companies: BiologicsMD and Neurexis Therapeutics. As Chief Scientific Officer at BiologicsMD, she oversees the pre-clinical development of biologic therapeutics aimed at treating alopecia, severe bone disorders, and metastatic breast and prostate cancers. In addition, as Vice President of R&D at Neurexis Therapeutics, she is involved in the development of neuroprotective therapies for the treatment and prevention of brain damage following stroke and heart attacks.
Her core expertise includes drug development, pharmaceutical manufacturing, and regulatory strategy. However, Dr. Goforth also oversees VIC’s evaluation process across a broad spectrum of areas, including therapeutics, medical devices, diagnostics, and life science technologies such as analytical instrumentation and bioprocessing equipment. She brings extensive experience in investment evaluation and the critical factors that contribute to the success of startups, guiding ventures from concept to commercialization.